Andrei V Krivtsov

List of Publications by Year
in descending order

59 papers	8,662 citations	126708 33 h-index	161609 54 g-index
65 all docs	65 docs citations	65 times ranked	12798 citing authors

#	Article	IF	Citations
1	Macrophage polarization in hypoxia and ischemia/reperfusion: Insights into the role of energetic metabolism. Experimental Biology and Medicine, 2022, 247, 958-971.	1.1	9
2	MOZ and Meninâ€œMLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer Discovery, 2022, 12, 1804-1823.	7.7	10
3	Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood, 2020, 136, 1983-1988.	0.6	25
4	Therapeutic targeting of preleukemia cells in a mouse model of <i>NPM1</i> mutant acute myeloid leukemia. Science, 2020, 367, 586-590.	6.0	145
5	A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	6.0	265
6	A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell, 2019, 36, 660-673.e11.	7.7	231
7	IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell, 2019, 24, 153-165.e7.	5.2	66
8	LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPÎ±-dependent enhancers in AML. Blood, 2018, 131, 1730-1742.	0.6	92
9	MEF2C Phosphorylation Is Required forÂChemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2018, 8, 478-497.	7.7	59
10	Peptidomimetic blockade of MYB in acute myeloid leukemia. Nature Communications, 2018, 9, 110.	5.8	68
11	TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics, 2018, 50, 83-95.	9.4	156
12	Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Advances, 2018, 2, 2478-2490.	2.5	12
13	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood, 2018, 131, 2661-2669.	0.6	313
14	Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026658.	2.9	46
15	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics, 2017, 49, 866-875.	9.4	75
16	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	5.8	55
17	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood, 2017, 130, 2631-2641.	0.6	102
18	Murine Retrovirallyâ€Transduced Bone Marrow Engraftment Models of MLLâ€Fusionâ€Driven Acute Myelogenous Leukemias (AML). Current Protocols in Pharmacology, 2017, 78, 14.42.1-14.42.19.	4.0	2

#	Article	IF	Citations
19	A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Molecular Cell, 2017, 67, 308-321.e6.	4.5	172
20	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine, 2016, 22, 672-678.	15.2	301
21	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	15.2	195
22	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	15.2	7
23	Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia. Blood, 2016, 128, 3945-3945.	0.6	0
24	Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia. Blood, 2016, 128, 436-436.	0.6	0
25	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. Blood, 2016, 128, 739-739.	0.6	0
26	Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research, 2015, 21, 2348-2358.	3.2	57
27	MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica, 2015, 100, e190-e193.	1.7	45
28	Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell, 2015, 17, 611-623.	5.2	97
29	Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature, 2015, 526, 273-276.	13.7	307
30	A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes and Development, 2015, 29, 2231-2243.	2.7	32
31	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	15.2	297
32	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. Blood, 2015, 126, 88-88.	0.6	0
33	AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes. Cancer Cell, 2014, 26, 896-908.	7.7	153
34	Regulation of HOX gene expression by AF10-mediated conversion of H3K79me1 to H3K79me2. Experimental Hematology, 2014, 42, S30.	0.2	0
35	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 2014, 124, 13-23.	0.6	139
36	Pathprinting: An integrative approach to understand the functional basis of disease. Genome Medicine, 2013, 5, 68.	3.6	13

#	Article	IF	Citations
37	Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L. Blood, 2013, 122, 1256-1256.	0.6	35
38	Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML. Blood, 2013, 122, 1328-1328.	0.6	2
39	Regulation Of Normal and Malignant Hoxa Gene Expression Through Higher H3K79 Methylated States. Blood, 2013, 122, 2492-2492.	0.6	2
40	The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Research, 2012, 40, D984-D991.	6.5	29
41	Can One Cell Influence Cancer Heterogeneity?. Science, 2012, 338, 1035-1036.	6.0	3
42	EVI1 is critical for the pathogenesis of a subset of MLL-AF9â€“rearranged AMLs. Blood, 2012, 119, 5838-5849.	0.6	76
43	MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L. Cancer Cell, 2011, 20, 66-78.	7.7	791
44	<i>MLL</i>-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1. Clinical Cancer Research, 2010, 16, 2122-2130.	3.2	39
45	The Wnt/Î²-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML. Science, 2010, 327, 1650-1653.	6.0	675
46	Transformation from Committed Progenitor to Leukemia Stem Cells. Annals of the New York Academy of Sciences, 2009, 1176, 144-149.	1.8	17
47	HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood, 2009, 113, 2375-2385.	0.6	292
48	Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood, 2009, 113, 3461-3471.	0.6	51
49	Gene Expression Profiling of Leukemia Stem Cells. Methods in Molecular Biology, 2009, 538, 231-246.	0.4	6
50	Cell of Origin Influences Leukemia Stem Cell Phenotype.. Blood, 2009, 114, 3459-3459.	0.6	6
51	H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias. Cancer Cell, 2008, 14, 355-368.	7.7	494
52	Jediâ€”a novel transmembrane protein expressed in early hematopoietic cells. Journal of Cellular Biochemistry, 2007, 101, 767-784.	1.2	21
53	MLL translocations, histone modifications and leukaemia stem-cell development. Nature Reviews Cancer, 2007, 7, 823-833.	12.8	1,039
54	Hoxa9+Meis1a Efficiently Transform Hematopoietic Stem Cells but Not Committed Progenitors.. Blood, 2007, 110, 3375-3375.	0.6	0

#	Article	IF	Citations
55	Transformation from committed progenitor to leukaemia stem cell initiated by MLLâ€"AF9. Nature, 2006, 442, 818-822.	13.7	1,317
56	Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors.. Blood, 2006, 108, 1994-1994.	0.6	0
57	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.. Blood, 2006, 108, 734-734.	0.6	2
58	Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO Journal, 2005, 24, 368-381.	3.5	111
59	Both SH2 Domains Are Involved in Interaction of SHP-1 with the Epidermal Growth Factor Receptor but Cannot Confer Receptor-directed Activity to SHP-1/SHP-2 Chimera. Journal of Biological Chemistry, 1997, 272, 5966-5973.	1.6	95